Do Sensor Glucose Levels Accurately Predict Plasma Glucose Concentrations During Hypoglycemia and Hyperinsulinemia?
Open Access
- 1 May 2002
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 25 (5) , 889-893
- https://doi.org/10.2337/diacare.25.5.889
Abstract
OBJECTIVE—The MiniMed Continuous Glucose Monitoring System (CGMS) measures subcutaneous interstitial glucose levels that are calibrated against three or more fingerstick glucose levels daily. The objective of the present study was to examine whether the relationship between plasma and interstitial fluid glucose is altered by changes in plasma glucose and insulin levels and how such alterations might influence CGMS performance. RESEARCH DESIGN AND METHODS—Arterialized plasma glucose, sensor glucose, and interstitial fluid glucose were measured by microdialysis in 11 healthy subjects during a 1.0 mU · kg−1 · min−1 stepped euglycemic-hypoglycemic-hyperglycemic (plasma glucose ∼5, 3.1, and 8.6 mmol/l, respectively) insulin clamp that raised plasma insulin to ∼360–390 pmol/l. RESULTS—When the CGMS was calibrated versus plasma glucose levels before insulin infusion, basal sensor and plasma glucose were similar (5.0 ± 0.3 vs. 5.2 ± 0.3 mmol/l, respectively); dialysate glucose was 3.3 ± 0.9 mmol/l. During the hyperinsulinemic-euglycemia study (plasma glucose 4.9 ± 0.3 mmol/l), dialysate glucose fell by 30–35%, accompanied by a significant reduction in sensor glucose (to 3.7 ± 0.6 mmol/l; P < 0.001 vs. plasma). Subsequently, sensor levels remained lower than plasma values during mild hypoglycemia (2.5 ± 0.6 vs. 3.1 ± 0.3 mmol/l; P < 0.01) and during recovery from hypoglycemia (7.3 ± 1.2 vs. 8.6 ± 0.6; P < 0.01). However, when the CGMS was calibrated against plasma glucose levels before and during each step of the clamp, sensor glucose levels increased throughout the study and did not differ from plasma glucose values during hypoglycemia. CONCLUSIONS—Although hyperinsulinemia may contribute to modest discrepancies between plasma and sensor glucose levels, the CGMS is able to accurately track acute changes in plasma glucose when calibrated across a range of plasma glucose and insulin levels.Keywords
This publication has 10 references indexed in Scilit:
- Continuous Subcutaneous Glucose Monitoring in Children With Type 1 DiabetesPediatrics, 2001
- Role of the Continuous Glucose Monitoring System in Pediatric PatientsDiabetes Technology & Therapeutics, 2000
- Interstitial glucose concentration and glycemia: implications for continuous subcutaneous glucose monitoringAmerican Journal of Physiology-Endocrinology and Metabolism, 2000
- Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot studyDiabetes Research and Clinical Practice, 1999
- Counterregulation in Peripheral Tissues: Effect of Systemic Hypoglycemia on Levels of Substrates and Catecholamines in Human Skeletal Muscle and Adipose TissueDiabetes, 1997
- Counterregulation of Hypoglycemia: Skeletal Muscle Glycogen Metabolism During Three Hours of Physiological Hyperinsulinemia in HumansDiabetes, 1995
- Effects of physiological hyperinsulinemia on counterregulatory response to prolonged hypoglycemia in normal humansAmerican Journal of Physiology-Endocrinology and Metabolism, 1994
- Microdialysis measurement of the absolute glucose concentration in subcutaneous adipose tissue allowing glucose monitoring in diabetic patientsDiabetologia, 1992
- Microdialysis—principles and applications for studies in animals and manJournal of Internal Medicine, 1991
- Influence of Continuous Physiologic Hyperinsulinemia on Glucose Kinetics and Counterregulatory Hormones in Normal and Diabetic HumansJournal of Clinical Investigation, 1979